Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
18/SC/0015	236685	HRA Approval	ACZ885: A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer(NSCLC)	No		21/12/2017	08/01/2018	23/02/2018	25/05/2018	12/06/2018	02/08/2018	Change over of nursing staff & PI long term sick	NHS Provider
14/SC/1346	151280	HRA Approval	National Lung Matrix Trial: Multi-drug,geneticmarker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer	No		12/01/2018	12/01/2018	15/07/2017				sub-contract delays from partner Trust - study in set-up	Neither
17/EM/0338	229242	HRA Approval	ABL001: A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	Yes	26/10/2018	28/07/2017	26/01/2018	31/01/2018	02/07/2018	09/07/2018	03/08/2018	Sub-contracting delays with partner Trust	Neither
17/SC/0661	227234	HRA Approval	CYTOFLOC: Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge) for post chemo-radiotherapy surveillance in patients with oesophageal cancer ? a feasibility study	No		18/12/2017	26/01/2018	23/01/2018	28/08/2018	17/08/2018	17/12/2018	Sponsor delay for activation due to Training of CCC Research Staff	Sponsor
17/NW/0634	209375	HRA Approval	COMICE: A randomized double blind placebo controlled Phase II clinical trial of Cediranib and Olaparib maintenance in advanced recurrent Cervical Cancer.	No		29/01/2018	29/01/2018	16/01/2018	21/09/2018	21/09/2018	25/09/2018	Delays in study set-up by CTU	Neither
14/NE/1240	163350	HRA Approval	PFIZER B1371012: A RANDOMIZED, DOUBLE-BLIND PHASE 1B/2 STUDY OF PF-04449913 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED INTERMEDIATE-2 OR HIGH-RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA WITH 20-30% BLASTS AND MULTI-LINEAGE DYSPLASIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA	No		03/02/2018	03/02/2018	06/03/2018	07/09/2018	13/09/2018	31/10/2018	sub-contract delays with partner Trust	Neither
18/NW/0031	230387	HRA Approval	net-02: A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of nanoliposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (NEC)	No		12/02/2018	12/02/2018	18/02/2018				Study in set-up - not open	Neither
17/YH/0187	218853	HRA Approval	PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma	Yes	03/10/2018	22/02/2018	22/02/2018	11/10/2017	22/06/2018	05/06/2018	27/09/2018	Sponsor delay in signing CTA and arranging SIV	Sponsor
17/WA/0111	225522	HRA Approval	HATCY: A Phase III, multicenter, randomised controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy (HATCY study)	No		25/09/2017	02/03/2018					Study in set-up - not open	Neither
15/SC/0103	154496	HRA Approval	SCALOP 2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/-nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer	No		14/02/2018	31/03/2018	26/07/2016				Study in set-up - not open	Neither
16/WM/0501	185601	HRA Approval	WISTERIA: A Phase I trial of WEE1 inhibition with Chemotherapy and Radiotherapy as adjuvant treatment, and a Window of Opportunity trial with Cisplatin in Patients with Head and Neck Cancer	No		08/02/2018	08/02/2018	28/02/2017	11/04/2018	29/03/2018	19/04/2018	complicated phase I pathway, complex contracting and finance negotiations	Both

Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
17/EM/0166	222665	HRA Approval	AVAIL-T: A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)	No		29/03/2018	29/03/2018	30/06/2017	19/09/2018	28/08/2018	22/10/2018	Sub-contracting delays with partner Trust	Neither
18/NE/0136	240494	HRA Approval	CheckMate 9DX- 0078/1587: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation	No		01/02/2018	04/05/2018	13/07/2018	08/08/2018	28/08/2018	28/09/2018	Delays with financial negotiations and sub-contract queries with partner Trust	Both
18/EM/0147	238388	HRA Approval	ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma	No		18/05/2018	11/06/2018	16/05/2018				Study not open - still in set-up	Neither
18/NW/0424	242807	HRA Approval	BEIGENE AME ? BGB?290-106: A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C] Pamiparib following Single Oral Dose Administration in Patients with Advanced and/or Metastatic Solid Tumors	No		01/08/2018	01/08/2018					Study not open - still in set-up	Neither
14/NI/1037	156193	HRA Approval	LYMRIT: A phase I/II study of 177Lu-HH1 (Betalutin?) radioimmunotherapy for treatment of relapsed CD37+ non-Hodgkin lymphoma	No		25/04/2018	25/04/2018					Study in set-up	Neither
15/EM/0440	178108	HRA Approval	AZTEC: A?phase?II?study?of?the?use?of?azacitidine?for?the?treatment?of?patientswith chronic graft?versus?host?disease who?have?failed therapy with corticosteroids	No		09/08/2017	04/04/2018	09/08/2016				Study in set-up	Neither
16/EM/0380	198726	HRA Approval	STUDY 15: A multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine	No		12/07/2018	12/07/2018	09/11/2016				Study in set-up	Neither
17/EM/0440	230556	HRA Approval	DANTE: A randomised phase III trial to evaluate the Duration of ANti-PD1 monoclonal antibody Treatment in patients with metastatic mElanoma	No		23/04/2018	05/06/2018	18/01/2018	12/09/2018	28/08/2018	26/10/2018	Sponsor delays - wrong CCC PI on IRAS	Sponsor
17/LO/0980	219505	HRA Approval	HALT - Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours	No		19/03/2018	30/05/2018	10/07/2017				Study in set-up	Neither
17/SC/0536	216069	HRA Approval	COPELIA: A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/Metastatic Endometrial Carcinoma or for disease relapse within 12 months of adjuvant carboplatin-paclitaxel chemotherapy.	No		05/12/2017	10/05/2018					Study in set-up	Neither
18/EM/0112	236871	HRA Approval	ALL-RIC: A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.	No		21/06/2018	21/06/2018	12/06/2018				Study in set-up	Neither
18/LO/0515	236848	HRA Approval	POLARIS : Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma	No		28/06/2018	28/06/2018	27/07/2018				Study in set-up	Neither
18/NE/0077	235979	HRA Approval	PORT: Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T cell lymphoma	No		16/07/2018	16/07/2018	31/05/2018				Study in set-up	Neither
18/NW/0290	226529	HRA Approval	FORMA 2102-HEM-101 PH2: A Phase 1/2, Multicenter, Open-label, Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 R132 Mutation	No		13/04/2018	30/05/2018	20/06/2018	10/12/2018	14/12/2018		Awaiting activation	Neither

Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
14/WS/1096	149204	HRA Approval	PARADIGM OlaPArib And RADiotherapy In newly-diagnosed GlioblastoMa: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study.	No		09/08/2017	09/01/2018	16/06/2016	28/06/2018	09/07/2018	24/10/2018	Delay due to the completion of the Phase I element of the study to be conducted as CCC taking part in Phase II only.	Neither
16/LO/0423	198451	HRA Approval	SIERRA-1: A Phase I trial of SRA737 (a CHK1 inhibitor) administered orally in subjects with advanced cancer	No		21/09/2017	24/01/2018	19/05/2017	05/06/2018	09/07/2018	09/11/2018	Delays due to sub-contracting with partner Trusts & ARSAC licence approval	NHS Provider
17/SC/0314	225425	HRA Approval	REPLIMUNE: An Open-Label, Multicenter, Phase 1/2 Study of RPI as a Single Agent and in Combination with Immune Checkpoint Blockade or Other Standard of Care Regimens in Patients with Solid Tumors	Yes	17/12/2018	16/08/2017	29/01/2018	30/08/2017	13/07/2018	23/08/2018	24/10/2018	Delays due to complex financial negotiations and confirmation from Gene Therapy Safety Committee	Both
18/YH/0139	237149	HRA Approval	Survival Outcomes and Interventions Pre and Post Treatment during the GWCA1208 Trial	Yes	10/10/2018	16/05/2018	16/05/2018	18/05/2018	14/08/2018	28/08/2018	26/10/2018	Delays due to complex financial negotiations with Sponsor.	Both
18/EM/0228	248988	HRA Approval	RSV-L: A double blind, placebo-controlled study to assess the antiviral effect, safety and tolerability of inhaled PC786 for the treatment of acute respiratory syncytial virus (RSV) infection in adult hematopoietic stem cell transplant recipients	Yes	11/12/2018	20/07/2018	25/07/2018	21/08/2018	22/10/2018	25/10/2018	08/11/2018	Sub-contracting delays with partner Trust	Neither
18/LO/1516	246850	HRA Approval	Q-ABC: A comparison of patient related outcomes following radical surgery and radiotherapy	Yes	07/12/2018	15/10/2018	08/11/2018	04/10/2018	13/11/2018	09/11/2018	23/11/2018	No delays	Neither
17/LO/1592	225931	HRA Approval	IMBRELLA: AN OPEN-LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN-LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY	No		11/04/2018	11/04/2018	07/11/2018	23/10/2018	19/11/2018	04/12/2018	Delay due to internal capacity issues within Finance Dept.	NHS Provider
17/LO/1869	230951	HRA Approval	TULIP: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer	No		19/11/2017	19/01/2018	16/01/2018	14/09/2018	26/09/2018	13/12/2018	Delay due to awaiting Trust ARSAC Licence; Sub-contract with partner Trust; internal imaging capacity; PI feedback on pathway; delay in study activation by sponsor	Both
17/SC/0090	215068	HRA Approval	c-TRAK TN: A randomised trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer	No		19/06/2017	08/01/2018	22/06/2017	09/10/2018	01/10/2018	14/12/2018	Delays due to sub-contract with partner Trust; PI delays; awaiting Trust ARSAC Licence; delay in activation by sponsor	Both
16/SC/0271	187103	HRA Approval	plasmaMATCH - A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening	No		28/04/2017	28/01/2018	21/09/2016	06/11/2018	03/10/2018	19/12/2018	Delays due to sub-contract with partner Trust; PI delay in feedback; awaiting Trust ARSAC Licence; delay in activation by sponsor	Both
18/SC/0444	249450	HRA Approval	Ask4More: A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response	No		12/10/2018	12/10/2018	25/09/2018				Study in set-up	Neither
17/LO/1727	181571	HRA Approval	EURONET: Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents	No		29/05/2018	29/05/2018	26/02/2018	15/08/2018	20/12/2018		Study in set-up	Neither

Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
17/LO/1875	219487	HRA Approval	Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage multi-centre randomised-controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.	No		10/11/2017	08/06/2018	08/01/2018				Study in set-up	Neither
17/LO/1808	231108	HRA Approval	ICON-9 An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy	No		19/07/2018	24/10/2018	18/12/2017				Study in set-up	Neither
18/WS/0099	245374	HRA Approval	BET Inhibitor 0610-02: A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Haematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)	No		30/05/2018	02/07/2018	02/07/2018				Study in set-up	Neither
18/LO/1859	252363	HRA Approval	ROIS: Observational cohort study of patients with hormone receptor-positive metastatic breast cancer treated with palbociclib (Ibrance?) as part of the United Kingdom Ibrance? Patient Program (IPP); the Real Outcomes Ibrance? Study (ROIS)	No		02/10/2018	25/10/2018	25/10/2018	11/12/2018	20/12/2018		Study in set-up awaiting activation	Neither
18/EM/0398	254915	HRA Approval	LEAP 002: Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapyof Participants with Advanced Hepatocellular Carcinoma (LEAP-002)	No		17/10/2018	23/11/2018					Study in set-up	Neither